AR1001: A Novel Oral Therapeutic Approach Addressing Unmet Needs

Alzheimer’s disease (AD) imposes substantial cognitive, functional, and societal burdens, with current emphasis on early intervention along the disease continuum. Treatment paradigms continue to rely predominantly on symptomatic agents and complex biologics requiring intensive monitoring and constrained by safety concerns. A growing global clinical consensus underscores the need for safe, accessible, mechanistically targeted agents that slow down, halt or reverse disease progression, administered early in the disease course. AR1001, an oral brain-penetrant phosphodiesterase-5 (PDE5) inhibitor, positions itself as a potential multimodal disease-modifying therapy (DMT).